Navigation Links
Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of,Docetaxel Chemotherapy

VIENNA, Austria, May 23, 2007-The chemotherapy drug docetaxel currently offers the best treatment for androgen-independent prostate cancer. That is the result of a now published clinical trial that compared the efficacy of the two most widely used chemotherapy drugs. When using docetaxel, the risk of disease progression was cut by more than 50% than when using the next-best chemotherapy drug.

The use of chemotherapy to treat prostate cancer has rapidly grown in importance over recent years, with several comprehensive clinical trials helping to drive forward progress. In two of these trials, the chemotherapy drug docetaxel offered patients a significantly improved prognosis. However, other clinical trials indicated that the drug vinorelbine, which like docetaxel acts on cellular microtubuli, also produces impressive results and it is often used as an alternative to docetaxel.

The Medical University of Vienna has now carried out the world¹s first direct comparison of both drugs, giving doctors valuable support in choosing the appropriate treatment for their patients.

TWO DRUGS ­ ONE CLEAR RESULT The trial clearly demonstrated the superior efficacy of docetaxel by using 40 patients to directly compare the drug against vinorelbine. The initiator and coordinator of the study, Prof. Michael Krainer, oncologist at the Department of Internal Medicine I, Medical University of Vienna, describes the outcome of the trial: "The median time to disease progression in all 20 patients we treated with docetaxel was more than three times longer than in the patients given vinorelbine." Cancerous tumours in patients from the first group did not progress for an average period of 14.5 months. In contrast, the median time to first disease progression in the patients treated with vinorelbine was only 4.4 months.

Values for "prostate-specific antigen" (PSA), an established tumour marker that indicate
'"/>




Page: 1 2 3

Related medicine technology :

1. Protox Announces Positive Clinical Data from Prostate Cancer Study
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
5. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
6. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
7. Quest PharmaTechs Prostate Cancer Program Update
8. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
9. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
10. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
11. Researchers Discover a Common Variation in a Gene Segment that Increases the Risk for Prostate Cancer
Post Your Comments:
(Date:5/26/2015)... DIEGO , May 26, 2015 ... a clinical-stage biopharmaceutical company leveraging its molecular adhesion ... therapies for sickle cell disease, heart failure, and ... an open-label, multicenter Phase 3 extension study of ... as "EPIC-E."  The study will enroll patients who ...
(Date:5/26/2015)... , May 26, 2015  Accuray Incorporated (Nasdaq: ... is scheduled to present at the Jefferies 2015 Healthcare ... Wednesday, June 3, 2015 at 2:30pm ET.   ... available on the Investor Relations page of the Company,s ... the presentation will begin approximately one hour after the ...
(Date:5/26/2015)... 26, 2015 Egalet Corporation (Nasdaq: ... company focused on developing, manufacturing and marketing innovative ... , president and chief executive officer, is scheduled ... will provide an update on Egalet,s marketed product ... Spray, approved product OXAYDO ™ (oxycodone HCI, ...
Breaking Medicine Technology:Mast Therapeutics Announces Initiation Of EPIC-E Study 2Mast Therapeutics Announces Initiation Of EPIC-E Study 3Mast Therapeutics Announces Initiation Of EPIC-E Study 4Mast Therapeutics Announces Initiation Of EPIC-E Study 5Egalet to Present at Upcoming Conferences in June 2Egalet to Present at Upcoming Conferences in June 3
... 2, 2011 Aoxing Pharmaceutical (NYSE Amex: ... company focusing on research, development, manufacturing and distribution ... operating subsidiary in China, Hebei Aoxing Pharmaceutical Group ... State Intellectual Property Office of The People,s Republic ...
... TARRYTOWN, N.Y., May 2, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... of America Merrill Lynch 2011 Health Care Conference on Tuesday, ... Eastern Time).  The session may be accessed through the Company,s ...  An archived version of the presentation will be available after ...
Cached Medicine Technology:Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 2Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 3
(Date:5/26/2015)... 3,000 senior industry executives are expected at ... future of the connected car. A very special attraction ... can read a driver’s brain waves. Visitors to its ... by mind alone just by gripping the steering wheel! ... are working on cognitive load, altering music based on ...
(Date:5/26/2015)... CO (PRWEB) May 26, 2015 It ... diverse community foundation in Colorado. On Wednesday, May 13, ... ushered in a new era of community-based giving with ... Titled “Our Future in the Making,” the event celebrated ... The Denver Foundation to mobilize resources for good. , ...
(Date:5/26/2015)... On May 26, 2015, My Positive Perspective ... distributor Dwayne Windfall. At the start of the episode, Deierlein ... some unique characteristics with it, so could you tell people ... saying, “I was reading the newspaper looking for a job ... looking for a person with hustle. I responded to the ...
(Date:5/26/2015)... Allprovide, the all-natural raw pet food company, today ... now available in three Georgia stores: Pooch-n-Paws in Suwannee; ... Dog Company in Kennesaw. , Allprovide is based out ... climate controlled facility. The fresh ingredients come from select ... food is triple-tested for quality. Unlike most pet foods, ...
(Date:5/26/2015)... CIO Review has chosen SIGNiX for its ... Technology Solution Providers. The positioning is based on an evaluation ... applicable across the entire security spectrum of transactions within life ... , “SIGNiX has been on our radar for some time ... Technology space, and we are happy to showcase them this ...
Breaking Medicine News(10 mins):Health News:The World’s Biggest Connected Car Exhibition is Back in Detroit 2Health News:The World’s Biggest Connected Car Exhibition is Back in Detroit 3Health News:Celebrating "Our Future in the Making" 2Health News:Celebrating "Our Future in the Making" 3Health News:My Positive Perspective Broadcasts Episode with Oceans 6 to Discuss Their Role in Helping the Community 2Health News:Allprovide, the All-Natural Pet Food, Available At Georgia Retailers 2Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 2Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 3
... PALO ALTO, Calif., April 23 Jazz,Pharmaceuticals, Inc. ... Cozadd, the,company,s Executive Chairman, will provide a corporate ... in Key Biscayne, FL,on May 1, 2008 at ... of the presentation may be accessed by visiting ...
... Technology could one day guide individualized therapy for cancer ... research suggests that scientists are close to developing a ... doctors a heads-up about what kind of treatment is ... into an emerging trend of individualized treatment for patients ...
... Inc. is pleased,to announce Corso Rehabilitation and Physical ... York State to offer the innovative and,non-surgical SpineSix ... pain,patients. Owned and operated by Gary Corso, MS, ... and Physical Therapy Associates provides,outstanding individualized care and ...
... Cream and, Limited-edition CD at Participating Giant Stores on Saturday, May ... ... April 23 ,Everyone,s a winner when you stop into participating Giant stores,throughout ... Triple Winner Game(R) Scoop Day event., This year, EDY,S Grand Ice ...
... 18% to $1.09; ... year, FRANKLIN LAKES, N.J., April 23 BD ... record quarterly revenues,of $1.747 billion for the second fiscal ... percent over the prior year period. This,quarter,s revenue growth ...
... Hurdles To Government Oversight & Gaining ... ... improved,governance structure, the benefits of nanotechnology may be difficult to,fully realize ... director of the Project on Emerging,Nanotechnologies (PEN). Rejeski testifies on Thursday, ...
Cached Medicine News:Health News:Scan Detects Oxygen Levels in Tumors 2Health News:The Future of Spine Care Has Just Gotten Better With the Use of SpineSix BioMotion Spinal System(TM) 2Health News:EDY'S(R) SLOW CHURNED(R) and Giant Food Markets Announce Scoop Day With Sweet Deals to Support the Fight Against Childhood Cancer 2Health News:BD Announces Results for Second Fiscal Quarter 2Health News:BD Announces Results for Second Fiscal Quarter 3Health News:BD Announces Results for Second Fiscal Quarter 4Health News:BD Announces Results for Second Fiscal Quarter 5Health News:BD Announces Results for Second Fiscal Quarter 6Health News:BD Announces Results for Second Fiscal Quarter 7Health News:BD Announces Results for Second Fiscal Quarter 8Health News:BD Announces Results for Second Fiscal Quarter 9Health News:BD Announces Results for Second Fiscal Quarter 10Health News:BD Announces Results for Second Fiscal Quarter 11Health News:BD Announces Results for Second Fiscal Quarter 12Health News:BD Announces Results for Second Fiscal Quarter 13Health News:BD Announces Results for Second Fiscal Quarter 14Health News:BD Announces Results for Second Fiscal Quarter 15Health News:Improved Governance Needed To Realize Nanotech's Benefits 2
... The VitalView™ Central Station is ... Criticare bedside monitors for vital signs ... displayed in real time, with simultaneous ... ECG events, graphical and tabular trends ...
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
... Chart Manager provides powerful workflow tools such ... integrated transcription services, and customized flow sheets ... eliminates the need for paper charts. ... a paperless office now and can easily ...
... The Cerner PowerChart Electronic Medical ... solutions designed to create an enterprise-wide, ... (EMR). PowerChart streamlines the workflow process ... access to the functions that support ...
Medicine Products: